A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
Purpose
The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric participants with Progressive Familial Intrahepatic Cholestasis (PFIC).
Condition
- Progressive Familial Intrahepatic Cholestasis (PFIC)
Eligibility
- Eligible Ages
- Between 1 Year and 17 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Informed consent and assent (as applicable) per Institutional Review Board/Ethics Committee (IRB/EC) 2. Male or female subjects with a body weight ≥5 kg, who are ≥12 months and <18 years of age at time of baseline 3. Cholestasis as manifested by total sBA ≥3× ULN (applies to primary cohort only) 4. An average AM ItchRO(Obs) score ≥1.5 during 4 consecutive weeks of the screening period, leading to the baseline visit (Visit 1) 5. Completion of at least 21 valid* morning ItchRO(Obs) entries during 4 consecutive weeks of the screening period, leading to the baseline visit (Visit 1) (*valid = completed and not answered as "I don't know"; maximum allowed invalid reports = 7, no more than 2 invalid reports during the last 7 days before randomization) 6. Diagnosis of PFIC based on the following: - Chronic cholestasis as manifested by persistent (>6 months) pruritus in addition to biochemical abnormalities and/or pathological evidence of progressive liver disease and - Primary Cohort: Subjects with genetic testing results consistent with biallelic disease-causing variation in ABCB11 (PFIC2), based on standard of care genotyping - Supplemental Cohort: i. Subjects with genetic testing results consistent with biallelic disease-causing variation in ATP8B1 (PFIC1), ABCB4 (PFIC3), or TJP2 (PFIC4), based on standard of care genotyping. ii. Subjects with PFIC phenotype without a known mutation or with another known mutation not described above or with intermittent cholestasis as manifested by fluctuating sBA levels. iii. Subjects with PFIC after internal or external biliary diversion surgery or for whom internal or external biliary diversion surgery was reversed. 7. Male and females of non-childbearing potential. Males and non-pregnant, non-lactating females of childbearing potential who are sexually active must agree to use acceptable methods of contraception during the study and 30 days following the last dose of the study medication. Females of childbearing potential must have a negative pregnancy test 8. Access to email or phone for scheduled remote visits 9. Ability to read and understand the questionnaires (both caregivers and subjects above the age of assent) 10. Access to consistent caregiver(s) during the study 11. Subject and caregiver willingness to comply with all study visits and requirements.
Exclusion Criteria
- Predicted complete absence of bile salt excretion pump (BSEP) function based on the type of ABCB11 mutation (PFIC2), as determined by a standard of care genotyping (applies to primary cohort only). Subjects can enter the study in the Supplemental Cohort (under inclusion criteria 6.ii or 6.iii). 2. Recurrent intrahepatic cholestasis, indicated by a history of sBA levels <3x ULN or intermittent pruritus (applies to primary cohort only) 3. Current or recent history (<1 year) of atopic dermatitis or other non-cholestatic diseases associated with pruritus. 4. History of surgical disruption of the enterohepatic circulation (applies to primary cohort only) 5. Chronic diarrhea requiring intravenous fluid or nutritional intervention for the diarrhea and/or its sequelae at screening or during the 6 months prior to screening 6. Previous or need for imminent liver transplant 7. Decompensated cirrhosis (international normalized ratio [INR] >1.5, albumin <30 g/L, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy) 8. ALT or total serum bilirubin (TSB) >15× ULN at screening 9. Presence of other liver disease 10. Presence of any other disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs, including bile salt metabolism in the intestine (e.g., inflammatory bowel disease), per Investigator discretion 11. Possibly malignant liver mass on imaging, including screening ultrasound 12. Known diagnosis of human immunodeficiency virus (HIV) infection 13. Any prior cancer diagnosis (except for in situ carcinoma) within 5 years of the screening visit (Visit 0) 14. Any known history of alcohol or substance abuse 15. Administration of bile acids or lipid binding resins, or phenylbutyrates during the screening period 16. Criterion has been deleted as of Amendment 3 17. Administration of any investigational drug, biologic, or medical device during the screening period 18. Previous use of an ileal bile acid transporter inhibitor (IBATi) 19. History of non-adherence to medical regimens, unreliability, medical condition, mental instability or cognitive impairment that, in the opinion of the Investigator or Sponsor medical monitor, could compromise the validity of informed consent, compromise the safety of the subject, or lead to nonadherence with the study protocol or inability to conduct the study procedures 20. Known hypersensitivity to maralixibat or any of its excipients.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Maralixibat |
Participants will receive Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks. |
|
|
Placebo Comparator Placebo |
Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks. |
|
More Details
- Status
- Completed
- Sponsor
- Mirum Pharmaceuticals, Inc.
Study Contact
Detailed Description
This study was conducted at multiple sites in North America, Europe, Asia and South America.